Ameriprise Financial Inc Glycomimetics Inc Transaction History

Ameriprise Financial Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$2.89 - $4.22 $47,075 - $68,739	-16,289 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$2.69 - $4.24 $21,121 - $33,292	-7,852 Reduced 32.53%	16,289 $61,000
Q3 2020 Nov 16, 2020	BUY	$3.07 - $5.0 $9,584 - $15,610	3,122 Added 14.85%	24,141 $74,000
Q2 2020 Aug 14, 2020	BUY	$2.06 - $3.76 $43,299 - $79,031	21,019 New	21,019 $79,000
Q1 2018 May 15, 2018	SELL	$16.06 - $25.35 $1.57 Million - $2.48 Million	-97,736 Closed	0 $0
Q4 2017 Feb 12, 2018	BUY	$10.51 - $17.22 $2,900 - $4,752	276 Added 0.28%	97,736 $1.64 Million
Q3 2017 Nov 07, 2017	BUY	$10.14 - $14.85 $988,244 - $1.45 Million	97,460	97,460 $1.36 Million

30.3M

51K

1.4K

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $14.2M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.